Tirzepatide Before and After: What the Clinical Evidence Actually Shows

*This article is for informational and educational purposes only. It is not medical advice. Compounded tirzepatide is not FDA-approved. All clinical data cited here reflects research using FDA-approved tirzepatide formulations (Zepbound, Mounjaro); results with compounded tirzepatide may differ. Individual results vary significantly. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

If you are researching tirzepatide, you have probably found the before-and-after photos. They are real, and for many people, the results are genuinely striking. But photos tell one dimension of what this medication does, and not always the most important one.

The SURMOUNT clinical trial program, which studied tirzepatide across multiple populations over multiple years, measured far more than body weight. Waist circumference, blood pressure, blood sugar, triglycerides, quality of life, and long-term weight maintenance all received rigorous attention. Together, that data gives a clearer picture of what tirzepatide actually changes in the body, and on what timeline, than any collection of testimonials can provide.

This article walks through what the trials measured, what they found, and what those findings mean for setting realistic expectations, especially for people in a compounded tirzepatide program.

---

How Tirzepatide Works: A Brief Primer

Before getting to the before-and-after data, it helps to understand why tirzepatide's results differ from earlier GLP-1 medications.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates two receptors at once: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Semaglutide activates only the GLP-1 receptor.

The dual mechanism appears to produce stronger effects on appetite reduction, gastric emptying, and insulin sensitivity than GLP-1 receptor agonism alone. This is the pharmacological basis for the larger weight loss numbers seen in tirzepatide trials compared to semaglutide trials, though direct head-to-head comparisons in the same population are still limited.

For more detail on how the medication works, see [how tirzepatide works](/resources/how-does-tirzepatide-work).

---

How Clinical Trials Define "Before and After"

In everyday use, before-and-after means photos and scale numbers. In clinical research, it means something more precise: a baseline measurement taken before the intervention, followed by serial measurements at defined checkpoints throughout the trial.

The SURMOUNT trials used standardized measurement protocols for body weight, body mass index (BMI), waist circumference, blood pressure, lipid panels, HbA1c, fasting glucose, and validated quality-of-life instruments. Participants were weighed and assessed at consistent intervals throughout treatment.

This structure matters for two reasons. First, it separates the question of "did tirzepatide cause these changes" from "did participants naturally improve." Placebo groups in these trials received identical lifestyle counseling and the same frequency of clinical attention; differences in outcomes between groups can be attributed to the medication itself rather than the program effects.

Second, time-series measurements reveal the shape of the response, not just the endpoint. Knowing that most weight loss occurs between months three and twelve, and that the rate slows but continues through the second year, changes how someone on treatment should interpret their own progress at any given moment.

---

Weight Outcomes Across the SURMOUNT Trials

The flagship SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight (without type 2 diabetes) and ran for 72 weeks. [1] Participants received once-weekly tirzepatide at 5 mg, 10 mg, or 15 mg, or a placebo, alongside lifestyle counseling.

The results across dose groups were:

• Tirzepatide 5 mg: Mean weight reduction of 15.0% from baseline
• Tirzepatide 10 mg: Mean weight reduction of 19.5% from baseline
• Tirzepatide 15 mg: Mean weight reduction of 20.9% from baseline
• Placebo: Mean weight reduction of 3.1% from baseline

A few context points are important for interpreting those numbers.

First, 72 weeks is eighteen months. The weight loss trajectory builds gradually over that full period. Participants who check their progress at eight or twelve weeks are seeing early-trajectory results, not end-of-treatment results. Most of the total weight loss accumulates between months three and twelve, with the rate slowing but continuing through month eighteen.

Second, the mean hides a wide range of individual responses. Some participants in SURMOUNT-1 lost more than 25% of body weight. Others lost closer to 8 to 10%. Variation in response is normal, not a sign that the medication is not working.

Third, the maximum dose in SURMOUNT-1 was 15 mg per week, reached through a structured titration schedule. Most programs begin at 2.5 mg weekly and increase gradually. The full appetite-suppressing effect builds as the dose increases.

For people with type 2 diabetes, SURMOUNT-2 reported somewhat lower but still substantial weight loss: 13.4% at 10 mg and 15.7% at 15 mg over 72 weeks. [2] The smaller effect in that population reflects the metabolic differences associated with type 2 diabetes, including insulin resistance and the blood-sugar-lowering effect of tirzepatide itself, which shifts some of the energy balance differently than in people without diabetes.

---

---

Beyond the Scale: What Else Changes

Weight loss is the most visible before-and-after marker, but the SURMOUNT trials tracked considerably more than the scale.

Waist Circumference

In SURMOUNT-1, participants receiving tirzepatide experienced substantial reductions in waist circumference from baseline. At 15 mg, mean waist circumference decreased by 18.5 cm compared to 3.8 cm in the placebo group. [1]

Waist circumference is a clinically meaningful measure because abdominal fat, particularly visceral fat surrounding internal organs, carries greater metabolic and cardiovascular risk than total body weight alone. Reductions in waist size often reflect preferential loss of visceral fat, which has downstream effects on insulin sensitivity, blood pressure, and inflammation.

Blood Pressure

Systolic blood pressure decreased meaningfully in the tirzepatide groups across SURMOUNT-1. Reductions of 5 to 7 mmHg were observed at the higher doses compared to the placebo group. [1] These changes appear to result from a combination of weight loss itself and direct effects of GLP-1 and GIP receptor agonism on the cardiovascular system.

For people managing hypertension, changes in blood pressure on tirzepatide may have implications for medication management, which is one reason having a provider supervise treatment matters.

Blood Sugar and HbA1c

In SURMOUNT-1, which enrolled participants without diabetes, tirzepatide still produced measurable improvements in fasting glucose and insulin sensitivity. The rate of progression to prediabetes or type 2 diabetes was lower in tirzepatide groups than in the placebo group over the 72-week period. [1]

In SURMOUNT-2, which specifically enrolled participants with type 2 diabetes, the blood sugar benefits were more pronounced. Mean HbA1c reductions of 1.7% at 10 mg and 2.1% at 15 mg were observed, with a substantial proportion of participants achieving HbA1c targets below 7% and 5.7%. [2]

Lipids and Metabolic Markers

Triglycerides, LDL cholesterol, and total cholesterol all improved in tirzepatide groups compared to placebo in SURMOUNT-1. [1] These changes reflect both the direct effects of weight loss on lipid metabolism and possible independent effects of GIP/GLP-1 receptor agonism on lipid processing.

HDL cholesterol, often called "good" cholesterol, increased modestly in tirzepatide groups, which is consistent with improvements in overall metabolic health associated with significant weight reduction.

---

The Timeline: When Do Results Appear?

Understanding the typical timeline of tirzepatide's effects is one of the most practically useful pieces of information for someone starting the medication.

Weeks one through four: The first dose adjustment period. Most people start at 2.5 mg weekly. Appetite suppression is often modest at this stage. Some people notice changes in hunger quickly; others notice little effect until the dose increases. Nausea is most common during this early period for many patients as the body adjusts.

Months two through four: The titration phase. Doses increase through 2.5, 5, and often 7.5 mg. Appetite suppression typically becomes more noticeable as doses rise. Weight loss begins to accelerate in most people. This is when many patients start noticing measurable changes on the scale.

Months four through twelve: The peak response period. Most of the total weight loss in SURMOUNT-1 accumulated during this window. Appetite suppression is typically most pronounced at or near the maximum tolerated dose. Weight loss continues to accumulate, though the weekly rate may slow as body weight decreases.

Months twelve through eighteen and beyond: The consolidation phase. In SURMOUNT-1, weight loss continued to consolidate through 72 weeks, with many participants reaching near-plateau by month twelve and making smaller additional gains through month eighteen. The trials showed that the effect is durable with continued treatment.

For a more detailed look at what the first four weeks feel like, see [tirzepatide first month: what to expect](/resources/tirzepatide-first-month-what-to-expect).

---

What Happens When You Stop

One of the most important "before and after" comparisons comes not from starting tirzepatide but from stopping it.

SURMOUNT-4 enrolled participants who had already achieved approximately 20.9% weight loss during an open-label tirzepatide phase, then randomized them to either continue tirzepatide or switch to placebo for 52 additional weeks. [3]

Participants who continued tirzepatide lost an additional 5.5% of body weight on average, reaching a total loss of approximately 25.3% from their original baseline. Those who switched to placebo regained approximately 14.8% of body weight over the same 52 weeks.

This finding reinforces a point that clinicians and researchers consistently emphasize: tirzepatide changes how the body regulates appetite and metabolism during active treatment. When the medication stops, those regulatory effects diminish, and body weight tends to partially or substantially return for most people. This is not a failure of willpower; it reflects the underlying biology of obesity as a chronic, relapsing condition.

SURMOUNT-3 extended this understanding by studying tirzepatide in people who had already achieved significant weight loss through intensive lifestyle intervention before starting the medication. [4] Beginning tirzepatide after lifestyle-achieved weight loss allowed participants to reach approximately 18.4% additional reduction in body weight from their post-lifestyle-intervention baseline, suggesting tirzepatide adds meaningfully on top of lifestyle changes rather than substituting for them.

---

Factors That Shape Individual Results

The SURMOUNT trials measured mean outcomes across thousands of participants. Individual results vary, sometimes substantially.

Starting weight: Percentage-based outcomes can translate to very different absolute weight losses depending on starting body weight. A 20% reduction means more pounds for someone starting at 250 lbs than at 180 lbs.

Dose reached: SURMOUNT-1 showed a clear dose-response relationship. People who tolerate and reach the 15 mg dose tend to see larger weight losses than those who stay at 5 mg or 10 mg due to side effects or clinical judgment.

Presence of type 2 diabetes: SURMOUNT-2 results were somewhat lower than SURMOUNT-1, reflecting the metabolic differences in that population. People with type 2 diabetes still saw meaningful weight loss, but the magnitude was somewhat less on average.

Lifestyle factors: All SURMOUNT participants received lifestyle counseling alongside medication. Nutritional choices and physical activity levels influence how much weight is lost and how well muscle mass is preserved during the process. See [what to eat on tirzepatide](/resources/what-to-eat-on-tirzepatide) for evidence-based dietary guidance.

Protein intake and exercise: Tirzepatide promotes weight loss from both fat and lean mass. Studies have found that adequate protein intake and resistance exercise help preserve muscle during treatment. See [tirzepatide and muscle loss](/resources/tirzepatide-muscle-loss-lean-mass) for more on this topic.

Genetics and metabolic history: Individual variation in GIP and GLP-1 receptor expression, baseline insulin sensitivity, and prior weight history all influence the response to tirzepatide. Some non-responders exist in every GLP-1 trial population.

---

A Note on Compounded Tirzepatide

If you are considering or currently using compounded tirzepatide through a telehealth program, the SURMOUNT data is useful as a reference point, but with an important caveat.

The trials studied the FDA-approved tirzepatide formulation (Zepbound, approved October 2023). Compounded tirzepatide is not FDA-approved. It has not been evaluated in the same clinical trials. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products.

That said, compounded tirzepatide is formulated to act on the same GLP-1 and GIP receptor pathways that the trials studied. The SURMOUNT data gives a reasonable reference for what the compound is designed to do and what outcomes look like at different doses in a well-designed clinical program with lifestyle support. Whether results with compounded tirzepatide will mirror, exceed, or fall short of SURMOUNT outcomes is not established by current evidence.

What is clear is that outcomes are shaped not just by the medication but by the program around it: provider oversight, dose management, lifestyle integration, and ongoing monitoring. [A telehealth program that provides all of these](/resources/compounded-tirzepatide-guide) offers a more complete context for treatment than medication alone.

---

Setting Realistic Expectations

The before-and-after data from SURMOUNT suggests a few clear takeaways for anyone starting or considering tirzepatide.

Weight loss of 15 to 20% of body weight is achievable for many people over 18 months with the higher doses of tirzepatide and appropriate lifestyle support. That is a clinically meaningful result that translates to improvements in blood pressure, blood sugar, waist circumference, and metabolic risk factors beyond what the scale alone captures.

The timeline is longer than social media before-and-after photos often imply. Meaningful results accumulate over six to twelve months, not six to twelve weeks. Early progress at lower doses is a sign that the medication is working as intended during titration, not a final result.

Continued treatment appears necessary to maintain most of the benefit. Stopping tirzepatide without transitioning to a maintenance plan leads to partial or substantial weight regain for most people.

Individual variation is real. Some people will lose more than the trial averages. Others will lose less. The mean outcome is a useful reference, not a personal prediction.

---

*Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Prescriva LLC, doing business as Prescriva, is not affiliated with, endorsed by, or sponsored by Eli Lilly.*

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded tirzepatide is not an FDA-approved medication. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products (Zepbound or Mounjaro).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Prescriva LLC, doing business as Prescriva, is a management services organization and does not practice medicine or make clinical decisions.

---

References

[1] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med*. 2022;387(3):205-216. PMID 35658024

[2] Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. 2023;402(10402):613-626. PMID 37385275

[3] Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. *JAMA*. 2024;331(1):38-48. PMID 38078870

[4] Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. *Nat Med*. 2023;29(11):2777-2785. PMID 37840095